Summit Therapeutics (SMMT) to Post Quarterly Earnings on Thursday

Posted by Francis Steltz on Jul 22nd, 2026

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) is anticipated to issue its Q2 2026 results after the market closes on Thursday, July 23rd. Analysts expect Summit Therapeutics to post earnings of ($0.26) per share and revenue of $0.1090 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 23, 2026 at 4:30 PM ET.

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last released its earnings results on Friday, May 1st. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03. On average, analysts expect Summit Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Summit Therapeutics Stock Up 8.4%

NASDAQ:SMMT opened at $14.63 on Wednesday. The business’s 50-day moving average price is $15.24 and its 200 day moving average price is $16.74. Summit Therapeutics has a 52-week low of $12.55 and a 52-week high of $30.98. The firm has a market cap of $11.36 billion, a P/E ratio of -9.14 and a beta of -1.26.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SMMT. Cantor Fitzgerald restated an “overweight” rating on shares of Summit Therapeutics in a research report on Friday, May 22nd. KeyCorp reiterated an “overweight” rating on shares of Summit Therapeutics in a report on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Summit Therapeutics in a research note on Friday. Stifel Nicolaus assumed coverage on shares of Summit Therapeutics in a report on Wednesday, April 8th. They set a “buy” rating and a $45.00 target price for the company. Finally, Truist Financial upgraded shares of Summit Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $26.97.

Check Out Our Latest Research Report on SMMT

Insider Buying and Selling

In related news, CFO Manmeet Singh Soni purchased 50,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were purchased at an average price of $14.45 per share, with a total value of $722,500.00. Following the purchase, the chief financial officer owned 3,123,603 shares of the company’s stock, valued at $45,136,063.35. This trade represents a 1.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Mahkam Zanganeh acquired 3,810,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were bought at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the acquisition, the chief executive officer owned 573,883,879 shares in the company, valued at approximately $7,529,356,492.48. This trade represents a 0.67% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 7,870,000 shares of company stock valued at $103,616,900. 83.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Summit Therapeutics

Several hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its position in Summit Therapeutics by 106.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,371,415 shares of the company’s stock worth $163,907,000 after purchasing an additional 4,832,592 shares in the last quarter. Readystate Asset Management LP acquired a new stake in shares of Summit Therapeutics in the fourth quarter worth $5,355,000. State Street Corp grew its holdings in shares of Summit Therapeutics by 4.3% during the fourth quarter. State Street Corp now owns 6,636,361 shares of the company’s stock valued at $116,070,000 after buying an additional 274,425 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Summit Therapeutics during the second quarter valued at $5,781,000. Finally, HRT Financial LP acquired a new position in Summit Therapeutics during the second quarter valued at $5,143,000. Hedge funds and other institutional investors own 4.61% of the company’s stock.

Summit Therapeutics Company Profile

(Get Free Report)

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.